Last reviewed · How we verify
Invasive Bladder Malignancy
Approved treatments
- Platinol-Aq · Pfizer
- adriacin · Chipscreen Biosciences, Ltd.
- Hydroxydaunorubicin · University of Colorado, Denver
- Liposomal Doxorubicin · Pfizer
- Doxorubicin Hydrochloride · Pfizer
Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division. - Hydroxydaunomycin · Weill Medical College of Cornell University
- Adriamycin · Johann Wolfgang Goethe University Hospital
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Invasive Bladder Malignancy patent landscape — cliff calendar, originator estates, attackable patents
- Invasive Bladder Malignancy treatment landscape brief
- Invasive Bladder Malignancy treatment updates RSS
Frequently asked questions about Invasive Bladder Malignancy
What drugs treat Invasive Bladder Malignancy?
Tracked treatments include Platinol-Aq, adriacin, Hydroxydaunorubicin, Liposomal Doxorubicin, Doxorubicin Hydrochloride, Hydroxydaunomycin, Adriamycin.
What is the treatment for Invasive Bladder Malignancy?
Standard treatment for Invasive Bladder Malignancy includes Platinol-Aq, adriacin, Hydroxydaunorubicin, Liposomal Doxorubicin, Doxorubicin Hydrochloride. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Invasive Bladder Malignancy patent cliff · Invasive Bladder Malignancy CI report
- Treatment: Platinol-Aq · Pfizer
- Treatment: adriacin · Chipscreen Biosciences, Ltd.
- Treatment: Hydroxydaunorubicin · University of Colorado, Denver
- Treatment: Liposomal Doxorubicin · Pfizer
- Treatment: Doxorubicin Hydrochloride · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing